SCHEMBL1636264

SCHEMBL1636264

C=CCC(C1CCCCC1)C(C#N)P(=O)(O)OC(C)CC

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SHBG P04278 1/20 0.33
ALDH1A1 P00352 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2072437 0.78
SCHEMBL1636261 0.78 MMP1 (0.35) SHBGALDH1A1NPSR1
SCHEMBL3668447 0.72
SCHEMBL869379 0.65 LAP3 (0.30)
SCHEMBL6074848 0.64
SCHEMBL1636054 0.64 ALDH1A1 (0.33) ALDH1A1NPSR1
SCHEMBL778739 0.63 MMP2 (0.34) SHBGNPSR1
SCHEMBL28056091 0.62 MMP2 (0.38) ALDH1A1NPSR1
SCHEMBL6487 0.61 LAP3 (0.32)
SCHEMBL28114244 0.60 DPP4 (0.35) SHBG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932261-B2 Macrocycle derivatives useful as inhibitors of β-secretase (BACE) JANSSEN PHARMACEUTICA NV (BE) 2011-04-26 US disclosed
US-20070232630-A1 MACROCYCLE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE) JANSSEN PHARMACEUTICA NV (BE) 2007-10-04 US disclosed
WO-2007092839-A2 MACROCYCLE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232630-A1 MACROCYCLE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE) BACE2, BACE1, PSEN2 SHBG 4476/4885ALDH1A1 4311/4885NPSR1 2434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.